Atlas Trials

Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer

Clinical trial NCT05188781 · COMPLETED

Trial details

NCT number
NCT05188781
Sponsor
The Affiliated Hospital of Qingdao University
Status
COMPLETED
Study type
OBSERVATIONAL
High-Grade Serous Ovarian Cancer
Start date
2019-01-04
Primary completion
2021-08-23
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.